The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? Tatham KC, Shankar-Hari M, Arabi YM. Intensive Care Med 2021 Oct 7. pii: 10.1007/s00134-021-06540.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tatham KC, Shankar-Hari M, Arabi YM. The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? Intensive Care Med 2021 Oct 7. pii: 10.1007/s00134-021-06540.
PMID: 34617150